AngioDynamics Secures CE Mark Approval In Europe For AlphaVac F18⁸⁵ System
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics has secured CE Mark approval in Europe for its AlphaVac F1885 System, which expands treatment options for healthcare professionals by reducing thrombus burden and improving right ventricular function in patients with pulmonary embolism (PE).
May 21, 2024 | 9:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AngioDynamics has received CE Mark approval for its AlphaVac F1885 System in Europe, which is expected to expand treatment options for healthcare professionals dealing with pulmonary embolism (PE). This regulatory milestone could enhance the company's market presence and drive revenue growth.
The CE Mark approval is a significant regulatory milestone that allows AngioDynamics to market the AlphaVac F1885 System in Europe. This could lead to increased adoption by healthcare professionals, thereby driving revenue growth and enhancing the company's market presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100